Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ascelia Pharma AB (publ) (ACE.ST)
Malmö, SE
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.05% | +5.65% | -8.56% | -4.17% | +4.18% | -8.00% | -22.74% | -81.05% | -91.11% | -87.98% | -87.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+54.7% ★ Q1'26: +43.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-140.6% Q1'26: -134.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+110.1% Q1'26: +32.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 33.33M (-100.0%)
|
89.63M
79.21M – 116.73M
+168.9% YoY
|
63.80M
36.79M – 73.19M
-28.8% YoY
|
71.00M
53.29M – 87.69M
+11.3% YoY
|
| EBITDA |
-67.69M
|
-71.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-67.77M
|
-71.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-80.03M
est: -37.32M (-114.5%)
|
-76.25M
est: -17.06M (-347.0%)
|
26.87M
10.21M – 46.51M
+257.5% YoY
|
11.24M
7.66M – 14.81M
-58.2% YoY
|
38.00M
21.46M – 41.47M
+238.2% YoY
|
| SGA |
16.39M
|
17.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.48
est: -0.72 (-106.9%)
|
-0.67
est: -0.15 (-341.4%)
|
0.25
0.09 – 0.41
+264.7% YoY
|
0.10
0.07 – 0.13
-60.0% YoY
|
0.28
0.19 – 0.37
+180.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Magnus O. Corfitzen | Chief Executive Officer | 4M | male |
| Andreas Norlin | Chief Scientific Officer | — | male |
| Anton Hansson | Chief Financial Officer | — | — |
| Jennie Wilborgsson | Chief Operating Officer | — | — |
| Mikael Widell | Head of IR & Communications | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACE.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
